Methyllycaconitine citrate

Overview

Methyllycaconitine (MLA) citrate is a blood-brain barrier-permeable antagonist of α7 nicotinic acetylcholine receptor ( α7nAChR ) with an IC 50 of 2 nM. Methyllycaconitine citrate inhibits Aβ 25-35 -induced autophagy by restoring the mTOR pathway, and prevents reactive oxygen species ( ROS ) production, microglial activation, reduced dopamine uptake, loss of dopaminergic terminals and catecholamine secretion. Methyllycaconitine citrate induces hippocampal glutamate efflux, enhances long-term potentiation, and improves memory acquisition. Methyllycaconitine citrate can be used in research related to Alzheimer's disease, cerebral palsy, Parkinson's disease and schizophrenia.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Alzheimer's Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > nAChR

Product Information

• Catalog No.: HY-N2332A
• CAS No.: 351344-10-0
• Molecular Formula: C43H58N2O17
• Molecular Weight: 874.92
• Purity: 98.88%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.08 mg/mL (2.38 mM); Clear solution
• Availability: In-stock

Source

Original product source